HP
PGNX

HealthInvest Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

HealthInvest Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-280,000
Closed -$1.77M – 19
2016
Q3 		$1.77M Buy
+280,000
New +$1.69M 1.32% 12

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

HealthInvest Partners's PGNX Position: Q4 2016 in Review

HealthInvest Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 280,000 shares — an estimated $1.77M sold.

HealthInvest Partners first reported a position in PGNX in Q3 2016 and held it in 1 quarter. The position peaked at $1.77M in Q3 2016. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • HealthInvest Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • HealthInvest Partners sold 280,000 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $1.77M.
  • HealthInvest Partners first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • HealthInvest Partners's Progenics Pharmaceuticals Inc position peaked at $1.77M in Q3 2016.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on HealthInvest Partners's 13F filing for Q4 2016, filed 24 Jan 2017.